Investor Presentaiton
Focusing on Weathering Near-Term Headwinds
While Positioning for Long-Term Growth
2017
Challenging generic
market conditions,
leading to price erosion
and volume decline
Gained some, lost some
in CRAM business
China site still faced a
financial loss
Focused on cost
reductions and portfolio
optimization
2018
Industry headwinds
expected to continue
Sales from CRAM projects
are expected to boost
Speed up momentum of
downstream integration
strategy by establishing
alliance with partner
Aggressively expand
formulation products
Further cost reductions
and portfolio optimization
Accelerate progress to
create positive cash flow
for Changshu site
2019 and beyond
Market conditions
expected to improve
Continue investment in
growth opportunities
Maintain high level of
quality and compliance
Strong pipeline to drive
growth from:
- CRAM business
- Drug products business
24
24
ScinoPharmView entire presentation